TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Hold” from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX) has received a consensus recommendation of “Hold” from the nine analysts that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $63.00.

A number of research analysts have weighed in on the stock. Zacks Research cut shares of TG Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, September 7th. HC Wainwright restated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research report on Tuesday, September 1st. Jefferies Financial Group restated a “buy” rating and issued a $83.00 price target on shares of TG Therapeutics in a research note on Monday, June 22nd. Bank of America upped their price target on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Finally, B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th.

Insider Activity at TG Therapeutics

In other news, Director Laurence Charney sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares of the company’s stock, valued at $9,268,454.40. This represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 8.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Cim Investment Management Inc. acquired a new position in TG Therapeutics during the second quarter worth $349,000. Envestnet Portfolio Solutions Inc. raised its position in shares of TG Therapeutics by 24.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 21,192 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 4,215 shares during the last quarter. Tidal Investments LLC acquired a new position in shares of TG Therapeutics during the 2nd quarter worth about $1,351,000. Gemmer Asset Management LLC purchased a new position in TG Therapeutics in the 2nd quarter valued at about $217,000. Finally, Engineers Gate Manager LP purchased a new position in TG Therapeutics in the 2nd quarter valued at about $589,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Down 3.9%

TG Therapeutics stock opened at $53.62 on Friday. The firm has a market cap of $8.21 billion, a PE ratio of 19.57, a P/E/G ratio of 2.39 and a beta of 1.80. TG Therapeutics has a 12 month low of $26.76 and a 12 month high of $59.30. The stock’s 50 day simple moving average is $53.74 and its two-hundred day simple moving average is $46.42. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.26). The firm had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business’s revenue for the quarter was up 70.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.17 earnings per share. Analysts anticipate that TG Therapeutics will post 0.92 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for B-cell-mediated diseases, including multiple sclerosis and B-cell malignancies. The company’s research and development activities center on antibody-based therapies designed to target B cells and related immune pathways.

TG Therapeutics’ principal marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.